X
ACHEMA MIDDLE EAST 2026
Pharma Advancement
DDF Summit 2025
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    idiopathic pulmonary fibrosis

    US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

    Tissue Repair Drug

    FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

    FastTrack Review

    US FDA Launches Fast-Track Review Scheme for Generic Drugs

    AI Based Drug Discovery

    Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

    wearable drug delivery devices

    Wearable Drug Delivery Devices for On-Demand Care

    biologic drug formulation stability

    Breakthroughs in Biologic Drug Formulation Stability

    high volume injectable formulations

    Overcoming Challenges in High-Volume Injectable Formulations

    lipid nanoparticles in RNA therapies

    Lipid Nanoparticles in RNA and Gene Therapies

    Breast Cancer Therapy

    US FDA Approves Breast Cancer Therapy Inluriyo by Eli Lilly

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    idiopathic pulmonary fibrosis

    US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

    Tissue Repair Drug

    FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

    FastTrack Review

    US FDA Launches Fast-Track Review Scheme for Generic Drugs

    AI Based Drug Discovery

    Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

    wearable drug delivery devices

    Wearable Drug Delivery Devices for On-Demand Care

    biologic drug formulation stability

    Breakthroughs in Biologic Drug Formulation Stability

    high volume injectable formulations

    Overcoming Challenges in High-Volume Injectable Formulations

    lipid nanoparticles in RNA therapies

    Lipid Nanoparticles in RNA and Gene Therapies

    Breast Cancer Therapy

    US FDA Approves Breast Cancer Therapy Inluriyo by Eli Lilly

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Americas

Unilateral Pricing Policy

Yuvraj_pawp by Yuvraj_pawp
14th March 2016
in Americas, News

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Alcon’s limited unilateral pricing policy applies only to new and innovative brands of contact lens and was introduced to encourage eye care professionals to educate their patients about the benefits of these breakthrough technologies. Alcon strongly believes that the UPP generates significant procompetitive benefits for consumers, eye care professionals, and the market for vision care products including, but not limited to: 1) encouraging ECPs to invest in learning about products covered by the UPP and educating their patients about the advantages of these products; 2) enhancing access to UPP products for consumers; 3) minimizing the ability of retailers to take advantage of the efforts of ECPs to educate their patients about UPP products; 4) encouraging innovation in new contact lens technologies; and 5) reducing unauthorized or “gray market” sales.

Eye Care for Everyone
UPP was implemented in support of Alcon’s introduction of Dailies Total1® water-gradient contact lenses; one of the most innovative lens to hit the U.S. market in at least a decade. Alcon believes cutting-edge technologies such as Dailies Total1® require additional investments of time and effort on the part of eye care professionals to educate their patients about these new contact lenses; fit and prescribe the lenses; and, follow-up, as appropriate.

By setting a reasonable minimum price, Alcon’s limited UPP fosters the ability and willingness of eye care professionals to provide services, by reducing the risk that other resellers – who do not invest in educating their customers about Alcon products and compete on price alone – will take advantage of these efforts.

Alcon applied UPP only to its new and most innovative lens technologies rather than our full contact lens portfolio. After Alcon introduced its UPP, other contact lens manufacturers chose to adopt their own unilateral pricing policies. In some cases, their policies appear to apply more broadly to encompass full lens brand portfolios. Alcon remains committed to applying its UPP only to new, and breakthrough lens technologies.

Alcon believes the Utah law violates the Commerce Clause of the US Constitution and is hopeful the Appeals Court will overturn the lower court’s ruling. Alcon was the first company to file a lawsuit in the U.S. District Court for the District of Utah challenging the law and seeking a preliminary injunction against its enforcement. When the District Court denied Alcon’s motion for preliminary injunction, permitting the law to take effect, we appealed to the Tenth Circuit.

While Alcon continues to defend its position in court, our focus remains on those efforts which have the greatest long-term benefit for our customers and the patients they serve. We therefore also dedicate our financial investments to: 1) developing breakthrough technologies that advance patient eye health; 2) selling our portfolio of contact lenses only to customers who purchase directly from Alcon or our authorized distributors; 3) enhancing consumer education about the advantages of contact lenses for vision correction; 4) further developing our Vision Care sales force, which provides both patient and product education to practitioners; and 5) supporting major initiatives that raise awareness about the importance of annual eye exams as well as humanitarian programs that grant access to vital eye care to those in need.

Tags: America
Previous Post

AbbVie and Boehringer Ingelheim announce global collaboration on promising immunology compounds

Next Post

Orexigen and Takeda Jointly Announce Orexigen's Acquisition of All Rights to CONTRAVE® in United States

Related Posts

idiopathic pulmonary fibrosis
Americas

US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

9th October 2025
Tissue Repair Drug
Clinical Trials

FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

7th October 2025
FastTrack Review
Americas

US FDA Launches Fast-Track Review Scheme for Generic Drugs

7th October 2025
AI Based Drug Discovery
Drug Development

Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

1st October 2025
API Manufacturing Facility
Americas

AbbVie Launches New API Manufacturing Facility in Illinois

1st October 2025
U.S. manufacturing
Americas

Amgen to Expand U.S. Manufacturing with $650M Investment

30th September 2025
Next Post

Orexigen and Takeda Jointly Announce Orexigen's Acquisition of All Rights to CONTRAVE® in United States

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In